Element Biosciences
Bryan has served on the Element Biosciences board of directors since September of 2017. He joined Venrock in 1997, and is currently a Partner based in Venrock’s Palo Alto office. Bryan focuses on a broad range of healthcare investments.
Bryan is currently involved with numerous public and private companies including 10X Genomics, Inscripta, Castlight Health, CloudFlare, Grand Rounds, Intarcia, and Lyra Health. Past investments include Ariosa Diagnostics (acquired by Roche), Athenahealth (NASDAQ: ATHN), Ikaria (acquired by Mallinckrodt), Illumina (NASDAQ: ILMN), Ironwood Pharmaceuticals (NASDAQ: IRWD), Sirna Therapeutics (acquired by Merck), and Zeltiq (acquired by Allergan). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has ranked on Forbes’ Midas List eleven times, 2008 – 2019.
Bryan received his PhD in Chemistry and Chemical Biology from Harvard University and his BA in Chemistry from Dartmouth College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices